Novel chimeric antigen receptor (CAR) T cells delivered directly to the CNS could have therapeutic effects in recurrent glioblastoma, according to two early-stage trials. If the effects are sustained and reproducible, the approach has potential to increase survival in the most lethal form of brain cancer.

Both sets of researchers had previously tested CAR T cells against the oncogenic epidermal growth factor receptor (EGFR) variant III by injecting the cells into the blood of people with glioblastoma. While administration of these cells proved safe, they had no therapeutic effect, leading both groups to develop novel CAR T cells.